What is the only marijuana derivative approved for cancer that acts as an oral antiemetic?

Marinol, which is the brand name for dronabinol, is the only marijuana derivative that has been specifically approved by the FDA for use as an oral antiemetic in patients undergoing chemotherapy for cancer. This medication contains synthetic tetrahydrocannabinol (THC), the psychoactive component of cannabis, and is utilized to help manage nausea and vomiting associated with cancer treatments. Its effectiveness in this role has been well-documented, which is why it has gained formal approval for medical use.

Recreational marijuana, while it may provide some relief for nausea, has not been approved by the FDA for this specific medical purpose and does not undergo the same rigorous testing for safety and efficacy required for prescription medications. Sativex, another cannabis-derived product, is primarily used for treating spasticity due to multiple sclerosis and is not approved specifically as an antiemetic. CBD oil, derived from hemp and containing little to no THC, does not have the same antiemetic properties and is not recognized by the FDA for treating nausea and vomiting in cancer patients.